SecBot SecBot

SYRE drug pipeline

Spyre Therapeutics, Inc. · 9 rated drugs
$99.37
−4.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
9
2 bullish · 1 mixed · 6 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2
Time to marketSPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.

SPY002 Updated Nov 4

What to watch

The next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.

Bull case
  • SPY002 met its Phase 2 SKYLINE Part A primary endpoint with a 10.7-point RHI reduction (p<0.0001), plus 33% clinical remission and 42% endoscopic improvement at Week 12, which the company characterizes as among the highest reported in UC.
  • Extended half-life (~75 days) enables potential quarterly or twice-annual subcutaneous maintenance dosing, a significant convenience advantage over first-generation competitors that require more frequent dosing.
  • All three IBD monotherapies (SPY001, SPY002, SPY003) achieved positive proof-of-concept in SKYLINE Part A, validating the platform and enabling the combination strategy in Part B.
Bear case
  • Intense TL1A competition: Roche (RVT-3101), Teva/Sanofi (duvakitug, Phase 3), and Merck (tulisokibart, Phase 3) are all ahead or at similar stages with first-generation anti-TL1A antibodies, and duvakitug already has positive Phase 2b maintenance data.
  • SPY072, a sibling anti-TL1A molecule, disappointed in rheumatoid arthritis (SKYWAY trial, August 2026), missing internal benchmarks and causing a stock decline, raising questions about the TL1A platform's breadth.
  • SKYLINE Part B combination data is not expected until Q3 2027, leaving a long data-free period during which the stock is exposed to competitive readouts and market sentiment.
● neutral
Impact
PhasePhase 2
Time to marketSPY072 is in Phase 2 clinical development. Even if the PsA/axSpA data are positive, the earliest potential approval would likely be 2029 or later, assuming successful Phase 3 trials and regulatory review.

SPY072 Updated Nov 4

What to watch

The next catalyst for SPY072 is topline data from the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY Phase 2 basket trial, expected in Q4 2026 (any day now). Positive data could partially rehabilitate the asset after the RA miss and support its development in rheumatic disease and as a component of the SPY772 combination for hidradenitis suppurativa. Weak data would further narrow SPY072's addressable opportunity and increase focus on the company's IBD pipeline (SPY001, SPY002, SPY003).

Bull case
  • SPY072 met its primary endpoint (DAS28-CRP) with statistical significance at Week 12 in the RA sub-study, demonstrating proof-of-mechanism for TL1A inhibition in rheumatic disease
  • Phase 1 data showed a ~75-day half-life, more than 3x longer than first-generation anti-TL1A antibodies, supporting potential quarterly or twice-yearly subcutaneous maintenance dosing
  • The SPY772 program combining SPY072 with a novel anti-IL-17A/F antibody opens a differentiated path in hidradenitis suppurativa, a large unmet-need market
Bear case
  • RA sub-study missed internal efficacy bar for monotherapy prioritization, causing the stock to fall ~12% on Aug 25, 2026, and raising questions about SPY072's differentiation in rheumatic disease
  • The anti-TL1A competitive field is crowded: Merck (tulisokibart) has Phase 3 UC data, Roche and Sanofi/Teva (duvakitug) are in Phase 3, and first-generation assets already have a head start in IBD and potentially rheumatic disease
  • SPY072's RA data showed only nominal significance on some endpoints (ACR20 with high dose, ACR50 with low dose) rather than consistent dose-response across all measures, suggesting modest efficacy
◆ mixed
Impact
PhasePhase 2
Time to marketSPY120 is in Phase 2 with Part B induction data expected in 2027. If successful, Phase 3 trials would follow, meaning potential approval is likely several years away (late 2029 or later under an optimistic scenario).

SPY120 Updated Nov 4

What to watch

The next major catalyst for SPY120 is the SKYLINE Part B induction readout expected in 2027. Positive data showing the SPY001+SPY002 combination outperforms either monotherapy would validate Spyre's combination strategy and likely drive the stock toward the $122.53 analyst mean target. Negative or equivocal data would raise serious doubts about the rationale for combining these mechanisms and could trigger significant downside given the stock's elevated short volume and the $10.3B market cap that already prices in substantial pipeline optimism.

Bull case
  • All three monotherapy components (SPY001, SPY002, SPY003) achieved proof-of-concept in SKYLINE Part A, with SPY003 described by management as 'potential best-in-class' (Sept 8, 2026 press release).
  • Preclinical data showed that combined alpha4beta7 and TL1A inhibition produced superior efficacy versus either monotherapy alone, providing a strong rationale for the SPY120 combination.
  • The YTE half-life extension technology could enable quarterly or twice-annual subcutaneous dosing, a major convenience advantage over current IBD therapies that require more frequent dosing.
Bear case
  • SPY120 is still in Phase 2 with no approved products or revenue; the SKYLINE Part B combination data (expected 2027) is a high-risk binary event that could fail to show superiority over monotherapies.
  • Spyre completed a dilutive $350M stock offering at $85/share in October 2026, increasing share count by ~4.1M shares (plus an underwriter option for another 0.6M).
  • Elevated short volume (64.2% of recent sessions' off-exchange volume vs a baseline of 58.1%, z-score 1.72) and insider selling under 10b5-1 plans signal bearish sentiment.
● neutral
Impact
PhasePhase 2
Time to marketSPY130 is in Phase 2 testing with combination data expected in Q3 2027. If successful, Phase 3 trials would follow, meaning potential approval is likely several years away, likely 2029 or later.

SPY130 Updated Nov 4

What to watch

The next major catalyst for SPY130 is the SKYLINE Part B combination data expected in Q3 2027. Positive results would validate the combination strategy and could accelerate the program toward Phase 3. Negative or mixed data would raise questions about the additive benefit of combining anti-alpha4beta7 and anti-IL-23 antibodies. Interim updates or enrollment completion announcements could move the stock in the interim.

Bull case
  • All three monotherapy components of SPY130 (SPY001, SPY002, SPY003) met their primary endpoints in Part A of the Phase 2 SKYLINE trial, providing a strong foundation for the combination study.
  • The SKYLINE Part B combination portion is enrolling faster than expected, enabling an increased enrollment target, suggesting strong investigator and patient interest.
  • SPY130 targets two validated IBD mechanisms (alpha4beta7 integrin and IL-23) with extended-half-life antibodies designed for quarterly or twice-annual subcutaneous dosing, potentially offering best-in-class convenience.
Bear case
  • SPY130 is still in Phase 2 with no topline combination data expected until Q3 2027, leaving a long wait with binary risk. The combination approach is unproven in the clinic; preclinical additive efficacy may not translate to humans.
  • Spyre reported a Q3 2026 net loss of $96.1M, widening sharply from $11.2M a year earlier, with operating cash burn of $77.5M in the quarter alone, raising questions about long-term capital efficiency.
  • The company completed a dilutive $350M public offering in October 2026 at $85/share, increasing share count by ~4.1M shares (roughly 5% dilution) and pressuring the stock.
● neutral
Impact
PhasePhase 2
Time to marketIf Part B data are positive in 2027, a Phase 3 program would follow, meaning potential approval is likely several years away (2029 or later), assuming successful trials.

SPY230 Updated Nov 4

What to watch

The next major catalyst for SPY230 is the SKYLINE Part B induction data readout, expected in Q3 2027 (roughly 10 months away). Positive data showing superiority of the SPY230 combination over its constituent monotherapies would validate Spyre's combination strategy and likely drive the stock higher. Negative or equivocal data would undermine the central thesis and could trigger significant downside given the premium valuation.

Bull case
  • All three monotherapy components of SPY230 (SPY001, SPY002, SPY003) achieved positive proof-of-concept in Part A of the SKYLINE trial, validating the biological rationale for the combination approach.
  • Preclinical data showed that combined TL1A and IL-23 inhibition produced additive efficacy over either monotherapy alone, and the extended half-life (~85 days for SPY003) supports potential quarterly or twice-annual dosing, a significant convenience advantage.
  • Analyst consensus is Strong Buy (21 buy/strong buy, 2 hold, 0 sell) with a mean price target of $122.53, implying ~23.4% upside from the Nov 4 close of $99.04.
Bear case
  • SPY230 is still in Phase 2 with no approved products or revenue; the company posted a $96.1M net loss in Q3 2026 and burned $77.5M in operating cash flow in the quarter.
  • The October 2026 $350M stock offering at $85/share (an 8.8% discount) diluted existing shareholders by roughly 4.1 million shares, and ongoing ATM sales add further dilution risk.
  • The TL1A target space is intensely competitive: Merck (tulisokibart) is already in Phase 3, and multiple bispecific programs (Roche, XmAb, ALX001) are in development, raising the bar for SPY230 to differentiate.
▲ bullish
Impact
PhasePhase 2
Time to marketSPY003 is in Phase 2 with no regulatory filing yet. The next major readout (SKYLINE Part B combination induction data) is expected in 2027. Assuming positive Phase 2 and subsequent Phase 3 trials, potential approval would likely be several years away, likely 2029 or later.

SPY003 Updated Nov 4

What to watch

The next major catalyst is SKYLINE Part B combination data expected in 2027, which will test whether pairing SPY003 with SPY001 (anti-alpha4beta7) or SPY002 (anti-TL1A) produces meaningfully better efficacy than monotherapy. Positive combination data would be a major derisking event for the entire platform; negative or underwhelming results would raise questions about the combination strategy's value proposition in a competitive IL-23 market. The company's strong cash runway into H2 2029 removes near-term financing risk.

Bull case
  • SPY003 met its Phase 2 Part A primary endpoint with high statistical significance (10.0-point RHI reduction, p<0.0001), achieving proof-of-concept for all three IBD mechanisms in Spyre's portfolio.
  • SPY003's ~85-day half-life is roughly 3x longer than risankizumab (Skyrizi), supporting potential quarterly or twice-yearly maintenance dosing, a significant convenience advantage over current standard-of-care IL-23 inhibitors.
  • The company has a very strong cash position of approximately $1.47 billion pro forma (as of September 30, 2026), providing runway into the second half of 2029 and fully funding the pipeline through multiple catalysts.
Bear case
  • IL-23 inhibitors are a crowded, commercially established class with AbbVie's Skyrizi (risankizumab) generating over $9 billion in 2024 revenue and J&J's Tremfya (guselkumab) and Lilly's mirikizumab already approved, making market entry challenging.
  • SPY003's Phase 2 Part A efficacy signals (20% clinical remission, 30% endoscopic improvement at 12 weeks) are in line with the IL-23 class but not clearly superior to approved drugs, raising questions about differentiation beyond dosing convenience.
  • Insider selling was heavy in September-October 2026: CEO Cameron Turtle and other executives sold multimillion-dollar blocks under 10b5-1 plans, which may signal limited near-term upside conviction.
● neutral
Impact
PhasePhase 2
Time to marketSPY001 is in Phase 2 trials. If Part B data is positive and the company proceeds to Phase 3, potential FDA approval is likely several years away, likely not before 2029-2030 at the earliest.

SPY001 Updated Nov 4

What to watch

The next major catalyst for SPY001 is the SKYLINE Part B induction data readout expected in 2027, which will test both monotherapy and combination regimens. Positive data could validate the combination strategy and strengthen the best-in-class thesis against Entyvio, while negative or mixed results would raise questions about the platform approach. In the interim, watch for any SKYLINE Part B enrollment updates, preclinical data presentations at medical conferences, and potential partnership or licensing announcements given the company's strong cash position.

Bull case
  • Phase 2 Part A data showed a 40% clinical remission rate and 51% endoscopic improvement at 12 weeks, among the highest rates reported in comparable UC trials, suggesting best-in-class potential versus Entyvio.
  • The drug is engineered with a half-life more than three-fold longer than vedolizumab, supporting potential quarterly or twice-annual maintenance dosing, a significant convenience advantage over Entyvio's monthly infusions.
  • Spyre has $1.5B in pro forma cash providing runway into the second half of 2029, eliminating near-term financing risk.
Bear case
  • SPY001 is still in Phase 2; Part B induction data is not expected until 2027, leaving a long period without a binary catalyst.
  • The drug faces entrenched competition from Takeda's Entyvio (vedolizumab), a blockbuster with over $5B in annual sales and deep physician familiarity.
  • Q3 2026 earnings missed consensus (-$0.94 vs -$0.785 expected), and the net loss widened to $96.1M from $11.2M a year ago.
● neutral
Impact
PhasePhase 2
Time to marketSPY007 is still in preclinical development, and the SPY772 coformulation has not yet entered clinical testing. The Phase 2 SKYLIGHT surrogate trial's topline data is expected in late 2027 or early 2028. If positive, the coformulation would still need to enter and complete clinical trials before any potential approval, putting commercialization several years away.

SPY772 Updated Nov 4

What to watch

SPY772 has no near-term catalyst; the next meaningful event is the SKYLIGHT Phase 2 topline readout in late 2027 or early 2028. For investors tracking Spyre, the more immediate catalysts are the ongoing SKYLINE Part B combination data (SPY001/SPY002/SPY003 pairwise combinations in IBD) and the company's progress toward pivotal studies. SPY772 is a long-duration option on HS expansion that will not resolve for over a year.

Bull case
  • SPY772 targets two validated inflammatory pathways (TL1A and IL-17A/F) in hidradenitis suppurativa, a disease with limited treatment options and significant unmet need.
  • Spyre has a strong balance sheet with approximately $1.5 billion in pro forma cash as of September 30, 2026, providing runway into the second half of 2029 to fund the SPY772 program and broader pipeline.
  • The SKYLIGHT trial uses a clever, capital-efficient surrogate design (evaluating SPY072 alongside bimekizumab) to generate proof-of-concept data before committing to the full coformulation.
Bear case
  • SPY772 is an early-stage combination program; SPY007 is still preclinical and has never been tested in humans, adding significant development risk.
  • Topline data from the Phase 2 SKYLIGHT trial is not expected until late 2027 or early 2028, more than 12 months away, meaning no near-term binary catalyst for this program.
  • SPY072, one of the two components, produced mixed results in its Phase 2 rheumatoid arthritis sub-study (statistically significant but missed internal benchmarks), raising questions about the TL1A mechanism in non-IBD indications.
● neutral
Impact
PhasePreclinical
Time to marketSPY007 is in preclinical development with no disclosed IND filing. Assuming successful preclinical work, Phase 1 initiation is likely at least 12-18 months away. Commercialization, if successful, would be several years out (likely 2030 or later).

SPY007 Updated Nov 4

What to watch

SPY007 is too early-stage to drive near-term stock movement. The next relevant catalyst for the SPY772 program (which includes SPY007) is the SKYLIGHT Phase 2 topline Week 16 HiSCR75 data, expected late 2027 or early 2028. Watch for any IND filing or Phase 1 initiation for SPY007 as a standalone molecule, which would signal advancement of this preclinical asset.

Bull case
  • SPY007 is built on Spyre's extended half-life antibody platform, which has shown differentiated PK profiles in other pipeline assets, potentially enabling quarterly or twice-annual dosing versus competitors' frequent injections.
  • The dual IL-17A/F mechanism is clinically validated by UCB's bimekizumab (Bimzelx), which is approved in psoriasis, psoriatic arthritis, and ankylosing spondylitis, reducing technical risk for SPY007.
  • Spyre has a strong cash position of approximately $1.47 billion pro forma (after October 2026 financing), providing runway into H2 2029 to advance SPY007 and the rest of the pipeline without near-term financing risk.
Bear case
  • SPY007 is still preclinical with no disclosed IND filing or clinical trial start, meaning it is years away from generating any clinical proof-of-concept data.
  • The SKYLIGHT Phase 2 trial is testing bimekizumab (an already-approved competitor drug) as the anti-IL-17A/F agent, not SPY007 itself, so SPY007's value proposition remains unvalidated.
  • Spyre has a large pipeline with multiple programs (SPY001, SPY002, SPY003, SPY072) that are more advanced, meaning SPY007 is a small part of a broader story and unlikely to be a near-term value driver.